The therapeutic potential of bikunin was also evaluated in a phase I trial involving nine patients with advanced uterine cervical carcinoma after definitive treatment, showing that bikunin was well tolerated by oral administration and was effective in suppressing uPA expression in tumor [67]. This evidence concerns the gene PLAU and neoplasm.